Fresh analysis reveals that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who halt conventional lifestyle programs.
Findings released in a prominent health publication shows that while overweight individuals can lose about a fifth of their total mass while using the jabs, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using these drugs should be cognizant of the risk of quick rebound weight gain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to starting weight within about a year and a half.
Comparing Approaches
The research, which looked at 37 of trials involving thousands of participants, contrasted the outcomes of the injectable medications with conventional dieting.
Scientists emphasize that people who shed pounds through dieting usually see a slower creep back—approximately 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Doctors suggest the mechanism of the drugs explains the amplified rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in appetite is no longer kept in check, making excessive eating much more probable."
A Chronic Issue?
Health authorities suggest the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, considering the significant potential of weight regain, the treatment might need to be life-long.
This view is supported by drug manufacturers, who state that the findings "emphasize the persistent character of obesity," comparing it to managing conditions like diabetes.
User Accounts
People who have stopped the jabs explain a powerful resurgence of hunger.
"It was like a switch activating and I was suddenly ravenous," recalled one woman.
The struggle is worsened if users have not developed permanent dietary or behavioural modifications during therapy.
Significant Interest
Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is more common among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, researchers emphasize that while the jabs are potent tools for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on integrated lifestyle changes.
